



Evrys Bio to Present at the H.C. Wainwright Liver Disease Virtual Conference

DOYLESTOWN, Pa., October 14, 2025 -- Evrys Bio, a biotech company developing transformative new, broad-spectrum antiviral therapeutics, today announced that Lillian Chiang, Ph.D., Chief Executive Officer, will present at the H.C. Wainwright Liver Disease Virtual Conference on Tuesday, October 21, 2025.

About Evrys Bio:

Evrys Bio is developing potential first-in-class host targeted antiviral therapeutics targeting SIRT2 to suppress viral infection and prevent drug-resistance. The Company's platform leverages allosteric, small molecule SIRT2 modulators that shift cellular metabolic reprogramming in order to simultaneously treat a broad spectrum of pathogens and overcome resistance. Evrys' lead program, EV-100, is being evaluated for the treatment of opportunistic infections in the transplant setting. Additional pipeline program indications include hepatitis B, medical countermeasures, key respiratory infections (RSV, Influenza A, B) tuberculosis and oncology.

For more information, please visit evrysbio.com.

Contact:

Investors and Media:

Argot Partners

evrys@argotpartners.com